Does the media refer more to PRME or CRBU?

In the previous week, Caribou Biosciences had 22 more articles in the media than Prime Medicine. MarketBeat recorded 31 mentions for Caribou Biosciences and 9 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Caribou Biosciences' score of 0.27 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PBYI or CRBU?

In the previous week, Caribou Biosciences had 26 more articles in the media than Puma Biotechnology. MarketBeat recorded 31 mentions for Caribou Biosciences and 5 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.84 beat Caribou Biosciences' score of 0.27 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRBU or CAPR?

In the previous week, Caribou Biosciences had 20 more articles in the media than Capricor Therapeutics. MarketBeat recorded 31 mentions for Caribou Biosciences and 11 mentions for Capricor Therapeutics. Caribou Biosciences' average media sentiment score of 0.27 beat Capricor Therapeutics' score of 0.26 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KMDA or CRBU?

In the previous week, Caribou Biosciences had 26 more articles in the media than Kamada. MarketBeat recorded 31 mentions for Caribou Biosciences and 5 mentions for Kamada. Caribou Biosciences' average media sentiment score of 0.27 beat Kamada's score of 0.26 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate YDES or CRBU?

Caribou Biosciences has a consensus target price of $5.50, indicating a potential upside of 1,095.13%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Caribou Biosciences 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.38

Which has better earnings & valuation, YDES or CRBU?

YD Bio has higher earnings, but lower revenue than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Caribou Biosciences $11.16M 4.42 -$148.12M -$1.08 N/A

Does the media favor YDES or CRBU?

In the previous week, Caribou Biosciences had 28 more articles in the media than YD Bio. MarketBeat recorded 31 mentions for Caribou Biosciences and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.27 beat Caribou Biosciences' score of 0.27 indicating that YD Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Caribou Biosciences (CRBU) Competitors

$0.46 -0.02 (-4.36%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+1.04%)

As of 10/9/2026 07:59 PM Eastern

Compare

CRBU vs. PRME, PBYI, CAPR, KMDA, and YDES

Should you buy Caribou Biosciences stock or one of its competitors? Caribou Biosciences's main competitors and comparable companies include Prime Medicine (PRME), Puma Biotechnology (PBYI), Capricor Therapeutics (CAPR), Kamada (KMDA), and YD Bio (YDES). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Caribou Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prime Medicine presently has a consensus price target of $7.47, indicating a potential upside of 87.27%. Caribou Biosciences has a consensus price target of $5.50, indicating a potential upside of 1,095.13%. Given Caribou Biosciences' higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Prime Medicine has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

In the previous week, Caribou Biosciences had 22 more articles in the media than Prime Medicine. MarketBeat recorded 31 mentions for Caribou Biosciences and 9 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Caribou Biosciences' score of 0.27 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caribou Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	156.31	-$201.14M	-$1.06	N/A
Caribou Biosciences	$11.16M	4.42	-$148.12M	-$1.08	N/A

Caribou Biosciences has a net margin of -1,030.42% compared to Prime Medicine's net margin of -4,613.11%. Caribou Biosciences' return on equity of -89.11% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Prime Medicine and Caribou Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Puma Biotechnology has a net margin of 11.50% compared to Caribou Biosciences' net margin of -1,030.42%. Puma Biotechnology's return on equity of 20.76% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Puma Biotechnology presently has a consensus price target of $6.00, suggesting a potential downside of 41.69%. Caribou Biosciences has a consensus price target of $5.50, suggesting a potential upside of 1,095.13%. Given Caribou Biosciences' higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Puma Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.33	$31.11M	$0.52	19.79
Caribou Biosciences	$11.16M	4.42	-$148.12M	-$1.08	N/A

In the previous week, Caribou Biosciences had 26 more articles in the media than Puma Biotechnology. MarketBeat recorded 31 mentions for Caribou Biosciences and 5 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.84 beat Caribou Biosciences' score of 0.27 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Puma Biotechnology beats Caribou Biosciences on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Capricor Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Capricor Therapeutics has higher revenue and earnings than Caribou Biosciences. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	4.42	-$148.12M	-$1.08	N/A
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A

Caribou Biosciences has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Capricor Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Capricor Therapeutics' return on equity of -56.60% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Capricor Therapeutics	N/A	-56.60%	-43.97%

In the previous week, Caribou Biosciences had 20 more articles in the media than Capricor Therapeutics. MarketBeat recorded 31 mentions for Caribou Biosciences and 11 mentions for Capricor Therapeutics. Caribou Biosciences' average media sentiment score of 0.27 beat Capricor Therapeutics' score of 0.26 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Caribou Biosciences currently has a consensus price target of $5.50, suggesting a potential upside of 1,095.13%. Capricor Therapeutics has a consensus price target of $30.25, suggesting a potential upside of 286.33%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Caribou Biosciences is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Caribou Biosciences beats Capricor Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Kamada?

Kamada (NASDAQ:KMDA) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Kamada has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.57	$20.20M	$0.38	21.26
Caribou Biosciences	$11.16M	4.42	-$148.12M	-$1.08	N/A

20.4% of Kamada shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Caribou Biosciences' net margin of -1,030.42%. Kamada's return on equity of 8.37% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

In the previous week, Caribou Biosciences had 26 more articles in the media than Kamada. MarketBeat recorded 31 mentions for Caribou Biosciences and 5 mentions for Kamada. Caribou Biosciences' average media sentiment score of 0.27 beat Kamada's score of 0.26 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Kamada presently has a consensus target price of $13.50, suggesting a potential upside of 67.08%. Caribou Biosciences has a consensus target price of $5.50, suggesting a potential upside of 1,095.13%. Given Caribou Biosciences' higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

Kamada beats Caribou Biosciences on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to YD Bio?

YD Bio (NASDAQ:YDES) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Caribou Biosciences has a consensus target price of $5.50, indicating a potential upside of 1,095.13%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

YD Bio has a beta of -1.55, suggesting that its share price is 255% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

YD Bio has higher earnings, but lower revenue than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Caribou Biosciences	$11.16M	4.42	-$148.12M	-$1.08	N/A

YD Bio has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. YD Bio's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

In the previous week, Caribou Biosciences had 28 more articles in the media than YD Bio. MarketBeat recorded 31 mentions for Caribou Biosciences and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.27 beat Caribou Biosciences' score of 0.27 indicating that YD Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Caribou Biosciences beats YD Bio on 9 of the 13 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.34M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-0.43	13.55	274.99	26.14
Price / Sales	4.42	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.35	17.17	11.22	6.33
Net Income	-$148.12M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-62.28%	-1.34%	-0.89%	-1.40%
1 Month Performance	-63.76%	-8.04%	-4.02%	-3.35%
1 Year Performance	-81.52%	14.18%	7.13%	1.49%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	3.0096 of 5 stars	$0.46 -4.4%	$5.50 +1,095.1%	-81.5%	$49.34M	$11.16M	N/A	97	Trending News Analyst Downgrade Analyst Revision Gap Down High Trading Volume
PRME Prime Medicine	3.463 of 5 stars	$2.95 +2.6%	$7.47 +153.0%	-29.8%	$531.99M	$4.63M	N/A	146
PBYI Puma Biotechnology	1.5521 of 5 stars	$9.83 +0.1%	$6.00 -38.9%	+101.0%	$508.20M	$228.40M	18.93	179	Analyst Upgrade
CAPR Capricor Therapeutics	2.9426 of 5 stars	$8.67 -0.4%	$30.25 +248.8%	+10.4%	$504.37M	$22.27M	N/A	231	Analyst Forecast
KMDA Kamada	4.9047 of 5 stars	$8.77 +1.7%	$13.50 +54.0%	+18.8%	$504.08M	$180.46M	23.07	462	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. PRME, PBYI, CAPR, KMDA, and YDES

How does Caribou Biosciences compare to Prime Medicine?

Summary

How does Caribou Biosciences compare to Puma Biotechnology?

Summary

How does Caribou Biosciences compare to Capricor Therapeutics?

Summary

How does Caribou Biosciences compare to Kamada?

Summary

How does Caribou Biosciences compare to YD Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. PRME, PBYI, CAPR, KMDA, and YDES

How does Caribou Biosciences compare to Prime Medicine?

Do institutionals & insiders believe in PRME or CRBU?

Do analysts recommend PRME or CRBU?

Which has more volatility and risk, PRME or CRBU?

Does the media refer more to PRME or CRBU?

Which has preferable valuation & earnings, PRME or CRBU?

Is PRME or CRBU more profitable?

Summary

How does Caribou Biosciences compare to Puma Biotechnology?

Do institutionals & insiders hold more shares of PBYI or CRBU?

Is PBYI or CRBU more profitable?

Do analysts rate PBYI or CRBU?

Which has more risk & volatility, PBYI or CRBU?

Which has stronger valuation & earnings, PBYI or CRBU?

Does the media refer more to PBYI or CRBU?

Summary

How does Caribou Biosciences compare to Capricor Therapeutics?

Which has preferable valuation and earnings, CRBU or CAPR?

Which has more risk & volatility, CRBU or CAPR?

Is CRBU or CAPR more profitable?

Does the media prefer CRBU or CAPR?

Do institutionals and insiders have more ownership in CRBU or CAPR?

Do analysts recommend CRBU or CAPR?

Summary

How does Caribou Biosciences compare to Kamada?

Which has stronger valuation and earnings, KMDA or CRBU?

Do institutionals & insiders have more ownership in KMDA or CRBU?

Is KMDA or CRBU more profitable?

Does the media favor KMDA or CRBU?

Which has more risk and volatility, KMDA or CRBU?

Do analysts recommend KMDA or CRBU?

Summary

How does Caribou Biosciences compare to YD Bio?

Do analysts rate YDES or CRBU?

Which has more risk and volatility, YDES or CRBU?

Do institutionals and insiders hold more shares of YDES or CRBU?

Which has better earnings & valuation, YDES or CRBU?

Is YDES or CRBU more profitable?

Does the media favor YDES or CRBU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools